Larazotide Acetate not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Larazotide acetate will be taken as oral capsules TID, at the dose assigned per the study arm. Duration of treatment is 14 weeks.”In the company’s words, NCT07944625 on ClinicalTrials.gov
- Tested for
- Celiac Disease, Celiac Disease in Adolescents
- Main trialPhase 3
- “The goal of this clinical trial is to learn if larazotide acetate, which will be tested at two doses and compared to placebo, can help prevent signs and symptoms of celiac disease in patients with well-controlled celiac disease who are following a gluten-free diet. Both adults and children (ages 12 years and up) will be allowed to enroll in this study.”In the company’s words, NCT07944625 on ClinicalTrials.gov
Other drugs for Celiac Disease
- FB102Forte Biosciences, Inc. · Phase 2
- DONQ52Roche · Phase 2
- ZED1227Dr. Falk Pharma GmbH · Phase 2
- AmlitelimabSanofi · Phase 2
- TEV-53408Teva Branded Pharmaceutical Products R&D LLC · Phase 2
Coming up1
- Aug 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07944625
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Aug 2028 | Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026